drugset / Trial / NCT01660620
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
Phase 1
Completed
23 enrolled
Smith-Kettlewell Eye Research Institute
Ohio State University · collabThe University of Texas Health Science Center, Houston · collabUniversity of Minnesota · collabUniversity of Oklahoma · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.
Timeline
- Start
- 2011-04
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | betaxolol | Small molecule | 0.25 % | Topical |
Indications
No indication recorded.